US equities |
SPCX $167.49 ▲+5.36% NVDA $237.17 ▲+1.38% MU $1,068.22 ▼-0.62% TSLA $376.37 ▲+1.56% MSFT $526.33 ▲+1.70% INTC $116.92 ▼-2.02% SNDK $1,724.49 ▲+0.26% META $744.91 ▲+2.31%
FinancialContent

Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

0.3532 +0.0056 (+1.61%)
Delayed Quote Updated: 10:54 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Heron Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
These stocks are moving in today's after hours session ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Heron (HRTX) Q2 2026 Earnings Call Transcript ↗
Patent setback forces guidance withdrawal as acute care revenue surges 44% year over year. 
Via The Motley Fool
Topics Earnings Intellectual Property
Heron Therapeutics Q1 Results Miss, but Acute Care Growth and Reaffirmed Outlook Support HRTX ↗
Via Chartmill
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Q4 2025 Revenue Beat and Positive 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Heron Therapeutics Q2 Earnings Call Highlights ↗
Heron Therapeutics (NASDAQ:HRTX) reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
Heron Therapeutics Announces Second Quarter 2026 Financial Results
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
U.S. District Court Issues Decision Regarding CINVANTI® Patents
After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal 
From Heron Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving after the closing bell on Monday? ↗
Via Chartmill
News headline image
Heron (HRTX) Q1 2026 Earnings Call Transcript ↗
Heron (HRTX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Supply Chain
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Heron Therapeutics Q1 Earnings Call Highlights ↗
Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving... 
Via MarketBeat
Topics Earnings
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron (HRTX) Q4 2025 Earnings Call Transcript ↗
Heron (HRTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Mixed Q3 2025 Results, Misses Revenue and Earnings Estimates ↗
Heron Therapeutics reported mixed Q3 2025 results, missing revenue and earnings estimates. Despite strong growth from its Acute Care products, the miss led to a negative market reaction. 
Via Chartmill
News headline image
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Heron Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >